Participant flow

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) · Source last updated 2026-01-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 50 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 50 mg once daily continuously.

   id

   FG000

   title

   Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg

2. description

   Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 100 mg sunvozertinib, followed by a 7-day washout period. Then, they received 100 mg sunvozertinib once daily continuously.

   id

   FG001

   title

   Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg

3. description

   Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 200 mg sunvozertinib, followed by a 7-day washout period. Then, they received 200 mg sunvozertinib once daily continuously.

   id

   FG002

   title

   Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg

4. description

   Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 300 mg sunvozertinib, followed by a 7-day washout period. Then, they received 300 mg sunvozertinib once daily continuously.

   id

   FG003

   title

   Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg

5. description

   Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy. Patients received a single dose of 400 mg sunvozertinib, followed by a 7-day washout period. Then, they received 400 mg sunvozertinib once daily continuously.

   id

   FG004

   title

   Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg

6. description

   Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 200 mg once daily dosing in the fasted state continuously.

   id

   FG005

   title

   Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State

7. description

   Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 300 mg once daily dosing in the fasted state continuously.

   id

   FG006

   title

   Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State

8. description

   Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 200 mg once daily dosing with a low-fat meal continuously.

   id

   FG007

   title

   Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal

9. description

   Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.

   id

   FG008

   title

   Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal

10. description

    Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.

    id

    FG009

    title

    Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal

11. description

    Patients with EGFR exon20ins, were refractory to, relapsed from, or intolerant to previous amivantamab treatment. No patient was enrolled into this cohort.

    id

    FG010

    title

    Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg

12. description

    Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy. Patients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.

    id

    FG011

    title

    Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted

Show more (12 of 15)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         2

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         1

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         2

      9. group Id

         FG008

         num Subjects

         1

      10. group Id

          FG009

          num Subjects

          4

      11. group Id

          FG010

          num Subjects

          0

      12. group Id

          FG011

          num Subjects

          0

      Show more (12 of 15)

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         4

      7. group Id

         FG006

         num Subjects

         4

      8. group Id

         FG007

         num Subjects

         2

      9. group Id

         FG008

         num Subjects

         2

      10. group Id

          FG009

          num Subjects

          3

      11. group Id

          FG010

          num Subjects

          0

      12. group Id

          FG011

          num Subjects

          1

      Show more (12 of 15)

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         0

      10. group Id

          FG009

          num Subjects

          0

      11. group Id

          FG010

          num Subjects

          0

      12. group Id

          FG011

          num Subjects

          0

      Show more (12 of 15)

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         1

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         1

      10. group Id

          FG009

          num Subjects

          0

      11. group Id

          FG010

          num Subjects

          0

      12. group Id

          FG011

          num Subjects

          0

      Show more (12 of 15)

      type

      site terminated by sponsor or non compliance

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         7

      5. group Id

         FG004

         num Subjects

         6

      6. group Id

         FG005

         num Subjects

         10

      7. group Id

         FG006

         num Subjects

         14

      8. group Id

         FG007

         num Subjects

         14

      9. group Id

         FG008

         num Subjects

         7

      10. group Id

          FG009

          num Subjects

          31

      11. group Id

          FG010

          num Subjects

          0

      12. group Id

          FG011

          num Subjects

          5

      Show more (12 of 15)

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         5

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         5

      5. group Id

         FG004

         num Subjects

         5

      6. group Id

         FG005

         num Subjects

         5

      7. group Id

         FG006

         num Subjects

         8

      8. group Id

         FG007

         num Subjects

         10

      9. group Id

         FG008

         num Subjects

         3

      10. group Id

          FG009

          num Subjects

          24

      11. group Id

          FG010

          num Subjects

          0

      12. group Id

          FG011

          num Subjects

          4

      Show more (12 of 15)

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         2

      5. group Id

         FG004

         num Subjects

         1

      6. group Id

         FG005

         num Subjects

         5

      7. group Id

         FG006

         num Subjects

         6

      8. group Id

         FG007

         num Subjects

         4

      9. group Id

         FG008

         num Subjects

         4

      10. group Id

          FG009

          num Subjects

          7

      11. group Id

          FG010

          num Subjects

          0

      12. group Id

          FG011

          num Subjects

          1

      Show more (12 of 15)

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice